Specify a stock or a cryptocurrency in the search bar to get a summary
Pharnext SA
ALPHAPharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of baclofen and acamprosate formulated as a pill for neurodegenerative diseases. The company was incorporated in 2007 and is headquartered in Suresnes, France. Address: 14 rue de la REpublique, Suresnes, France, 92150
Analytics
WallStreet Target Price
11 604.91 EURP/E ratio
–Dividend Yield
101203.43 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ALPHA
Dividend Analytics ALPHA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALPHA
Stock Valuation ALPHA
Financials ALPHA
Results | 2019 | Dynamics |